Firefly Neuroscience Inc (AIFF) News

Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care

Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective...

Form DEF 14A - Other definitive proxy statements

This Micro Cap Soared On Key Announcement

A Virginia-based medical tech company found a crazy amount of success on Tuesday following an announcement that the company is advancing its...

Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform

KENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Firefly Neuroscience Closes on Financing of up to $12.4 Million

TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”...

Form 8-K - Current report

Form 8-K - Current report

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]